We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Isothermal Amplification Based COVID-19 Test System Could Detect Any Coronavirus Variant

By LabMedica International staff writers
Posted on 29 Dec 2021
Print article
Illustration
Illustration

Researchers have developed a strategy to create a cheap and rapid COVID-19 test based on isothermal amplification that will make it possible to create universal test systems for any of the COVID-19 variants.

The strategy developed by researchers at the HSE University (Moscow, Russia) will decrease the cost of COVID-19 tests considerably and speed up the process, since no specially trained professionals or expensive equipment will be needed. There are several options for systems that detect traces of SARS-CoV-2 in human blood or secretion samples. They usually detect either scraps of COVID-19’s pathogen RNA using polymerase chain reaction (PCR) and its analogues, or antibodies to COVID-19. Usually, quite a lot of time is required for such a test, from 30 minutes to several hours, which is why researchers are looking for new, faster methods to detect antibodies or COVID infection.

The Russian researchers have been working on another alternative to PCR tests that is based on so-called loop-mediated isothermal amplification (LAMP). This testing approach allows for multiplication of certain DNA or RNA fragments from bio samples with the use of special markers and ferments of extremophilic bacteria that reside in hot springs. The key advantage of LAMP over PCR is that all reactions can be made at the same temperature. This simplifies and speeds up the process. But these systems are much more complicated to develop and have a few drawbacks, which has previously limited their use in COVID-19 test systems. The new strategy developed by the researchers will help overcome these drawbacks and give healthcare professionals an opportunity to use LAMP testing to detect traces of any COVID variants in samples of mucus and blood without preliminary processing in a laboratory.

Related Links:
HSE University 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.